Summit Therapeutics Inc.
SMMT
#1799
Rank
$11.352 B
Marketcap
United States
Country
$14.23
Share price
-5.86%
Change (1 day)
-10.24%
Change (1 year)
Categories
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company…
Key Metrics
Trailing P/E
—
Forward P/E
-19.85
EPS (TTM)
$-1.14
Forward EPS
$-1.19
Price / Book
22.10
EV / EBITDA
-15.2x
Beta
-1.24
Dividend Yield
—
Return on Equity
-192.50%
Return on Assets
-101.61%
Debt / Equity
3.24
Current Ratio
6.96
Gross Margin
0.00%
Operating Margin
0.00%
Net Profit Margin
0.00%
Free Cash Flow
$-139,678,496
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 13 – Sep 11
+25.36%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$705.0K
Latest Net Income$-78,782,000
Reporting periods1
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Summit Therapeutics Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
SMMT
No recent news available. Set FINNHUB_API_KEY to enable news.
